Ionis Pharmaceuticals — Jan 12, 2026 release

ions, achieved 2025 preliminary U.S. net product sales of $105M* as first FDA-approved treatment for FCS; sNDA for sHTG submitted for review – -            Increasing annual TRYNGOLZA peak net sales guidance to >$2B for sHTG –  -            Positive topline results announced for pivotal Phase 3 program of bepirovirsen in chronic hepatitis B; first of five Phase 3 readouts from partnered programs expected this year – CARLSBAD, Calif., January 12 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at the 44 th Annual J.P. Morgan Healthcare Conference   on Tuesday, January 13 at 8:15am PT; the presentation is available today on the Ionis website here . “2025 was a defining year for Ionis, as we successfully executed our first two independent launches as a commercial stage biotech company. We expect 2026 to be another transformative year, poised for two additional independent launches of breakthrough therapies – olezarsen for severe hypertriglyceridemia, Ionis’ first launch in a large patient population, and zilganersen for Alexander disease, Ionis’ first independent launch from our leading neurology pipeline,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “This momentum is further bolstered b